BriaPro Acquires Exclusive Soluble CD80 License from

BriaCell Therapeutics and BriaPro Therapeutics announced the completion of a previously announced asset purchase transaction for BriaPro to acquire BriaCell’s exclusive license to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer and related assets.

Under the purchase agreement dated February 4, 2026, BriaPro received worldwide rights to develop and commercialize sCD80, while the University of Maryland, Baltimore County (UMBC) retains patent ownership with certain government-retained rights. BriaPro will pay UMBC a 2% royalty upon commercialization and will fund research and development through a credit facility that can provide up to $3 million to BriaCell, subject to BriaCell approval for each drawdown. As consideration, BriaPro issued 23,972,589 common shares to BriaCell at an aggregate value of approximately C$1.18 million.